The researchers of this study conducted a systematic review of literature on polysomnographic differences between patients with narcolepsy and healthy controls.
To learn more about the potential role of cannabinoids in the management of sleep disorders, we interviewed Aleksandra M. Kwasnik, MD, who recently coauthored a review on the topic.
The NDA submission is supported by data from the phase 3 REST-ON study.
This retrospective study assessed the presence of orthostatic intolerance in pediatric patients with primary hypersomnia disorders soon after diagnosis.
Study researchers evaluated the ability of the multiple sleep latency test and polysomnography to distinguish patients with narcolepsy from those with other non-narcoleptic central disorders of hypersomnolence.
The AS03-adjuvanted H1N1 influenza vaccine was linked to an increased narcolepsy incidence, but this narcolepsy did not clinically differ significantly from sporadic cases.
Sodium oxybate treatment may be associated with weight reduction and stabilization in children with type 1 narcolepsy.
A recent study showed that COVID-19 quarantining has led to people going to bed later, getting up earlier, and getting lower quality sleep, the impact of the COVID-19 pandemic on patients with narcolepsy has not yet been determined.
Obesity, night eating, parasomnia, sleep talking and drunkenness, and ADHD symptoms are more frequent in children than adults at narcolepsy diagnosis.
The FDA has approved Xywav™ oral solution for the treatment of cataplexy or EDS in patients aged ≥7 years with narcolepsy.
